SAR 127963Alternative Names: SAR127963
Latest Information Update: 16 Jul 2016
At a glance
- Originator Sanofi
- Mechanism of Action Nerve growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Brain injuries in France
- 31 Mar 2012 Phase-I clinical trials in Brain injuries in France (unspecified route)